Myriad ( Myriad )

Myriad

Myriad's picture

Myriad is dedicated to providing patients and physicians with clinically important information globally. As part of this, Myriad has established International Headquarters in Zurich, Switzerland, a full service laboratory in Munich, Germany and sales offices in Munich, Germany, Paris, France, Madrid, Spain, Milan, Italy and Zurich, Switzerland. Additionally, we are working with a number of distributors globally.

Myriad press release, blog etc

04/19/2018 - 04:39 Myriad Announces Launch of "Go Green" Sustainability Initiative In Support of Earth Day
04/02/2018 - 05:24 Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan
03/06/2018 - 07:10 Myriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate Cancer
03/01/2018 - 02:58 Myriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Awareness Month
02/20/2018 - 04:34 NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer
02/15/2018 - 13:24 JAMA Oncology Publication Demonstrates EndoPredict (EPClin) Significantly Outperforms Oncotype DX Recurrence Score in Early-Stage Breast Cancer
02/07/2018 - 04:55 Myriad's myRisk Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation
01/22/2018 - 02:53 Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer
01/12/2018 - 01:27 Myriad Receives FDA Approval of BRACAnalysis CDx as Companion Diagnostic for Lynparza (olaparib) In Patients with Metastatic Breast Cancer
01/03/2018 - 06:01 Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
12/12/2017 - 06:29 Myriad's BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP Inhibitor, Talazoparib
12/08/2017 - 16:56 Myriad Genetics Presents Results From Two Important EndoPredict Studies at the 2017 San Antonio Breast Cancer Symposium
12/06/2017 - 16:31 Myriad Genetics Presents Pivotal Validation Study for New riskScore Test at the 2017 San Antonio Breast Cancer Symposium
11/10/2017 - 06:49 Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight Test to Improve Mental Health Outcomes for Veterans
11/06/2017 - 08:54 Myriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED) Study for the Vectra DA Test
11/02/2017 - 08:19 Myriad Announces GeneSight Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
10/30/2017 - 06:57 Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting
10/26/2017 - 06:17 EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX (RS) in Women with Intermediate Risk of Breast Cancer Recurrence